SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
March 20, 1997
Date of report (Date of earliest event reported)
K-V PHARMACEUTICAL COMPANY
(Exact name of Registrant as specified in its charter)
Delaware 1-9601 43-0618919
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.)
incorporation)
2503 South Hanley Road, St. Louis, Missouri 63144
(Address of principal executive offices) (Zip Code)
(314) 645-6600
(Registrant's telephone number, including area code)
<PAGE>
Item 9. Sales of Equity Securities Pursuant to Regulation S
On March 20, 1997, K-V Pharmaceutical Company (the "Company") completed
its sale of 200,000 previously unissued shares of the Company's Class A Common
Stock, par value $0.01 per share, to Roche International, Ltd. of Hamilton,
Bermuda for cash consideration in the amount of $3,500,000 in a transaction
exempt from the registration requirements of the Securities Act of 1933 by
reason of Regulation S promulgated thereunder.
2
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereto duly authorized.
Date: April 2, 1997
K-V PHARMACEUTICAL COMPANY
By: /s/ Gerald R. Mitchell
---------------------------
Gerald R. Mitchell
Vice President - Finance
3
